Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.